Interplay between obesity, low-grade inflammation, and hormonal biomarkers: A case-control study

Z. L. Hassan

doi:10.15421/0226029

Z. L. Hassan University of Samarra

Keywords: obesity, inflammation, hormonal biomarkers, adipokines, insulin resistance, dyslipidemia.

Abstract

Obesity is a complex metabolic disorder associated with chronic low-grade inflammation and significant hormonal imba l ances. The aim of the research presented here was to e xplore the interrelationship between obesity, inflammation, and hormonal biomarkers, focusing on how inflammatory mediators and hormonal alterations contribute to the development of metabolic and cardiovascular complications associated with obesity. This case-control study (Jan uary –Apr il 2024, Samarra, Iraq) included 55 obese women as subjects (BMI ≥30 kg/m², aged 24–55) and 35 healthy wo men (BMI 18.5–24.9) as controls. Participants with chronic diseases, pregnancy, or metabolic drugs were excluded. After ethical approval and consent were given , fasting blood (10 mL ) was collected for serum analysis of adipokines , inflammatory markers, insulin, ghrelin , and lipid profile using ELISA. Fas t ing glucose, HOMA-IR, QUICKI, and lipid parameters (LDL-C, VLDL-C) were calculated per standard protocols. The study revealed significant differences between the obese and control groups across all parameters. Obese participants had higher BMI, lipid profile (TC, TG, LDL-C, VLDL-C), and lower HDL-C. Fasting glucose, HbA1c, insulin, and HOMA-IR were elevated, while QUICKI decreased, indicating insulin resistance. There was increased adipokines ( asprosin , resistin , PAI-1) and inflamm a tory markers ( calprotectin , lipocalin-2) and reduced neuregulin-4 and ghrelin . All this confirms that there are strong relationships between obesity, dyslipidemia , inflammation, and hormonal imbalance. Chronic l ow grade inflammation and disrupted produ c tion of adipokines is strongly related with obesity, dyslipidemia , insulin resistance, and hormonal imbalance. Such alterations lead to metabolic dysfunction, elevated cardiovascular and diabetes risks, which means that early intervention and specific treatments help to restore homeostasis in metabolism.

References

de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., Mendes, C. G., Tofano, V. A. C., & dos Santos Haber, J. F. (2021). Adipokines, myokines, and hepatokines: Crosstalk and metabolic repercussions. International Journal of Molecular Sciences, 22(5), 2639.

Deng, M., Aberle, M. R., van Bijnen, A. A. J. H. M., van der Kroft, G., Lenaerts, K., Neumann, U. P., Wiltberger, G., Schaap, F. G., Olde Damink, S. W. M., & Rensen, S. S. (2023). Lipocalin-2 and neutrophil activation in pancreatic cancer cachexia. Frontiers in Immunology, 14, 1159411.

Georgoulis, M., Chrysohoou, C., Georgousopoulou, E., Damigou, E., Skoumas, I., Pitsavos, C., & Panagiotakos, D. (2022). Long-term prognostic value of LDL-C, HDL-C, lp(a) and TG levels on cardiovascular disease incidence, by body weight status, dietary habits and lipid-lowering treatment: The ATTICA epidemiological cohort study (2002–2012). Lipids in Health and Disease, 21(1), 141.

Kabadi, U. M. (2021). Diabetes mellitus: Disorder of cellular dysfunction due to lack of entry into cell of glucose. The most efficient fuel for cellular function. Open Journal of Endocrine and Metabolic Diseases, 11(3), 79–101.

Kawai, T., Autieri, M. V., & Scalia, R. (2021). Adipose tissue inflammation and metabolic dysfunction in obesity. American Journal of Physiology-Cell Physiology, 320(3), C375–C391.

Khanna, D., Khanna, S., Khanna, P., Kahar, P., & Patel, B. M. (2022). Obesity: A chronic low-grade inflammation and its markers. Cureus, 14(2), e22711.

Koenen, M., Hill, M. A., Cohen, P., & Sowers, J. R. (2021). Obesity, adipose tissue and vascular dysfunction. Circulation Research, 128(7), 951–968.

Kosmas, C. E., Rodriguez Polanco, S., Bousvarou, M. D., Papakonstantinou, E. J., Peña Genao, E., Guzman, E., & Kostara, C. E. (2023). The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics, 13(5), 929.

Luo, F., Das, A., Khetarpal, S. A., Fang, Z., Zelniker, T. A., Rosenson, R. S., & Qamar, A. (2024). ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases. Trends in Cardiovascular Medicine, 34(4), 215–222.

Mitoiu, B. I., Nartea, R., & Miclaus, R. S. (2024). Impact of resistance and endurance training on ghrelin and plasma leptin levels in overweight and obese subjects. International Journal of Molecular Sciences, 25(15), 8067.

Mohammadshahi, J., Ghobadi, H., Matinfar, G., Boskabady, M. H., & Aslani, M. R. (2023). Role of lipid profile and its relative ratios (cholesterol/HDL-C, triglyceride/HDL-C, LDL-C/HDL-C, WBC/HDL-C, and FBG/HDL-C) on admission predicts in-hospital mortality COVID-19. Journal of Lipids, 2023, 6329873.

Neacă, I., Negroiu, C. E., Tudorașcu, I., Dănoiu, R., Moise, C. G., Toader, D. M., & Dănoiu, S. (2025). Risk factors and outcomes of hemorrhagic transformation in acute ischemic stroke following thrombolysis: Analysis of a single-center experience and review of the literature. Medicina, 61(4), 722.

Ogbodo, E. C., Onah, C. E., Amah, A. K., Okeke, C. S., Obiorah, M. O., Okezie, A. O., Ogalagu, R. O., Iwuji, J. C., Mbam, R. E., & Meludu, S. C. (2024). Assessment of fasting plasma glucose, insulin, insulin resistance and glycated haemoglobin as markers of glycemic control in apparently healthy older adults in Nnewi. Indian Journal of Forensic and Community Medicine, 11(2), 49–55.

Palma, G., Sorice, G. P., Genchi, V. A., Giordano, F., Caccioppoli, C., D’Oria, R., Marrano, N., Biondi, G., Giorgino, F., & Perrini, S. (2022). Adipose tissue inflammation and pulmonary dysfunction in obesity. International Journal of Molecular Sciences, 23(13), 7349.

Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023). Obesity and type 2 diabetes mellitus: Connections in epidemiology, pathogenesis, and treatments. Frontiers in Endocrinology, 14, 1161521.

Saenz-Pipaon, G., Ravassa, S., Larsen, K. L., Martinez-Aguilar, E., Orbe, J., Rodriguez, J. A., Fernandez-Alonso, L., Gonzalez, A., Martín-Ventura, J. L., Paramo, J. A., Lindholt, J. S., & Roncal, C. (2022). Lipocalin-2 and calprotectin potential prognosis biomarkers in peripheral arterial disease. European Journal of Vascular and Endovascular Surgery, 63(4), 648–656.

SantaCruz-Calvo, S., Bharath, L., Pugh, G., SantaCruz-Calvo, L., Lenin, R. R., Lutshumba, J., Liu, R., Bachstetter, A. D., Zhu, B., & Nikolajczyk, B. S. (2021). Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities. Nature Reviews Endocrinology, 18(1), 23–42.

Santos-Pereira, M., Pereira, S. C., Rebelo, I., Spadella, M. A., Oliveira, P. F., & Alves, M. G. (2023). Decoding the influence of obesity on prostate cancer and its transgenerational impact. Nutrients, 15(23), 4858.

Tahapary, D. L., Pratisthita, L. B., Fitri, N. A., Marcella, C., Wafa, S., Kurniawan, F., Rizka, A., Tarigan, T. J. E., Harbuwono, D. S., Purnamasari, D., & Soewondo, P. (2022). Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and tryglyceride/glucose index. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16(8), 102581.

Theodorakis, N., Kreouzi, M., Pappas, A., & Nikolaou, M. (2024). Beyond calories: Individual metabolic and hormonal adaptations driving variability in weight management – a state-of-the-art narrative review. International Journal of Molecular Sciences, 25(24), 13438.

Vekic, J., Stromsnes, K., Mazzalai, S., Zeljkovic, A., Rizzo, M., & Gambini, J. (2023). Oxidative stress, atherogenic dyslipidemia, and cardiovascular risk. Biomedicines, 11(11), 2897.

Yuan, X., Wang, J., Yang, S., Gao, M., Cao, L., Li, X., Hong, D., Tian, S., & Sun, C. (2022). Effect of intermittent fasting diet on glucose and lipid metabolism and insulin resistance in patients with impaired glucose and lipid metabolism: A systematic review and meta-analysis. International Journal of Endocrinology, 2022, 6999907.

Zollner, A., Schmiderer, A., Reider, S. J., Oberhuber, G., Pfister, A., Texler, B., Watschinger, C., Koch, R., Effenberger, M., Raine, T., Tilg, H., & Moschen, A. R. (2020). Faecal biomarkers in inflammatory bowel diseases: Calprotectin versus lipocalin-2 – a comparative study. Journal of Crohn’s and Colitis, 15(1), 43–54.

Zoroddu, S., Di Lorenzo, B., Paliogiannis, P., Mangoni, A. A., Carru, C., & Zinellu, A. (2024). Resistin and omentin in breast cancer: A systematic review and meta-analysis. Clinica Chimica Acta, 562, 119838.